These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30390311)

  • 1. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
    Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
    Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
    Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
    Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.
    How J; Hobbs GS
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1271-1278. PubMed ID: 32886896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
    Tefferi A; Guglielmelli P; Nicolosi M; Mannelli F; Mudireddy M; Bartalucci N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Begna KH; Naseema Gangat ; Pardanani A; Vannucchi AM
    Leukemia; 2018 Jul; 32(7):1631-1642. PubMed ID: 29654267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
    Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
    Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.
    Kuykendall AT; Talati C; Padron E; Sweet K; Lancet JE; List AF; Sallman D; Komrokji RS
    Am J Hematol; 2019 Dec; 94(12):E314-E317. PubMed ID: 31444809
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
    Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
    Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
    Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
    Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
    Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
    Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
    Samuelson Bannow BT; Salit RB; Storer BE; Stevens EA; Wu D; Yeung C; Fang M; Petersdorf EW; Linenberger ML; Woo J; Sorror ML; Doney K; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):386-392. PubMed ID: 28970176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
    Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
    Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation.
    Stevens EA; Jenkins IC; Beppu LW; Zhang Q; Salit R; Loeb KR; Deeg HJ; Radich JP
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1371-1374. PubMed ID: 32194289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.